Download Spanish trial patients at biochemical relapse: results of the

Haematologica HAEMATOL/2015/128439 Version 3
Haematologica
HAEMATOL/2015/128439
Version 3
Zoledronic acid as compared with observation in Multiple Myeloma
patients at biochemical relapse: results of the randomized AZABACHE
Spanish trial
Disclosures: This work was supported with an unrestricted grant from NOVARTIS
FARMACEUTICA S.A., Barcelona, Spain. Part of the work was also done thanks to the
grants PS09/01450 and PI12/02311 from the Spanish “Instituto de Salud Carlos III
(ISCIII)”, the grant RD12/0036/0069 from “Red Temática de Investigación Cooperativa en
Cáncer (RTICC), and grant GCB-120981SAN from the “Asociación Española Contra el
Cáncer (AECC)” that financed some of the biological data of these patients.
Contributions: RG-S and JFSM were the initial designers of the study. MVM was involved in the
initial launch of the study, provided strong documental and scientific support and helped in the
statistical and clinical interpretation of the data. AO, MJM, JdlR, AR, MTH, LP, AIT, MJB, MG, PR,
JB, EA, MG, EMO, and JMR, were clinicians responsible for the patients and those who took care of
the protocol accomplishment, sampling and collection of clinical data. RG-S and MVM prepared the
initial version of the paper. JFSM and RG-S were the main responsible of the global group. JFSM
was the main representative of the GEM/PETHEMA group. RG-S, JFSM and MVM were the
persons responsible of the final revision of the draft, as well as the persons who gave the final
approval of the version to be published.